23.47

3.07% +0.70

Rocket Pharmaceuticals Inc (RCKT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rocket Pharmaceuticals Inc stock is currently priced at $23.47, with a 24-hour trading volume of 627.15K. It has seen a +3.07% increased in the last 24 hours and a -7.71% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $22.69 pivot point. If it approaches the $23.71 resistance level, significant changes may occur.

Previous Close:

$22.77

Open:

$23.63

24h Volume:

627.15K

Market Cap:

$2.13B

Revenue:

Net Income/Loss:

$-245.60M

P/E Ratio:

-7.0906

EPS:

-3.31

Net Cash Flow:

$-211.39M

1W Performance:

+6.78%

1M Performance:

-7.71%

6M Performance:

+11.87%

1Y Performance:

+32.15%

1D Range:

$23.30

$24.00

52W Range:

$14.89

$32.52

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name

Rocket Pharmaceuticals Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

646-440-9100

Address

430 East 29th Street, Suite 1040, New York, NY

Employee

Twitter

@rocketpharma

Next Earnings Date

2024-05-02

Latest SEC Filings

RCKT's Discussions on Twitter

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Feb-01-23	Initiated	Morgan Stanley	Overweight
Nov-08-22	Initiated	Canaccord Genuity	Buy
Nov-01-22	Initiated	BTIG Research	Buy
Jul-08-22	Initiated	Raymond James	Outperform
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy
Feb-18-21	Initiated	Needham	Buy
Dec-16-20	Initiated	UBS	Buy
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy
Feb-05-19	Initiated	Oppenheimer	Outperform
Sep-13-18	Initiated	Ladenburg Thalmann	Buy
Jul-10-18	Initiated	William Blair	Outperform

View All

Rocket Pharmaceuticals Inc Stock (RCKT) Latest News

Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga

Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data

Rocket Pharmaceuticals Inc (RCKT) Net Income 2024

RCKT net income (TTM) was -$245.59 million for the quarter ending December 31, 2023, a -10.70% decrease year-over-year.

Rocket Pharmaceuticals Inc (RCKT) Cash Flow 2024

RCKT recorded a free cash flow (TTM) of -$211.39 million for the quarter ending December 31, 2023, a -13.19% decrease year-over-year.

Rocket Pharmaceuticals Inc (RCKT) Earnings per Share 2024

RCKT earnings per share (TTM) was -$2.94 for the quarter ending December 31, 2023, a +9.82% growth year-over-year.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, as well as a strategic research collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.